The MDCG updates the IVDR Implementation and Preparation Plan (EU) 2017/746
Joint implementation and preparedness plan for Regulation (EU) 2017/746 on In Vitro Diagnostic Medical Devices (IVDR) has been updated.
Meditrial offers strategic-regulatory consulting services. We can help you to comply with the new regulation requirements.
The document underlines that the implementation of the IVDR has proven to be a very challenging task for the whole sector and all concerned: stakeholders, the European Commission and Member States. In order to meet the challenges related to implementation of the IVDR, all actors involved should work closely together.
This paper reassesses the implementation priorities and sets out a joint plan of the Member States and the Commission services, including concrete priority actions in order to have an operational system in place before the date of application (May 26, 2022) and provide key supporting elements as soon as possible.
The main aim of this paper, however, is to agree on where to focus limited resources in the shorter term to ensure delivery as soon as possible and by the date of application.
What are the priorities?
The document divides the priorities into two sets:
- Set A includes actions that are vital for devices to have access to the market (those related to a framework for contingency planning and availability of notified bodies).
- Set B includes legislation and guidance documents that, while not obligatory, would greatly facilitate the work of the actors as well as designation of EU reference laboratories for high-risk IVDs.
Read more.
How to prepare for the implementation of the IVDR Regulation (EU) 2017/746?
- Perform a precise Gap Analysis.
- Check the new classification rules for IVD devices.
- Check the Technical Documentation.
- Rely on a team of experienced IVD experts to implement the strategies and actions needed to be ready by May 26, 2022.
Meditrial team of medical, regulatory and technical experts will assist you to efficiently bring innovative in vitro diagnostics to market. Contact us today!
Table of Contents
Getting a CE mark for medical devices: a step-by-step guide
Practical guidance on the CE mark for medical devices under EU MDR, from classification and evidence to conformity assessment and EUDAMED
A Practical RBQM Framework for Medical Device Trials
Risk-based quality management for medical device trials, with practical actions for risk assessment, monitoring, data review, and trial oversight
EU Breakthrough Medical Devices Under MDCG 2025-9 (BtX)
EU breakthrough medical devices gain a clearer regulatory pathway under MDCG 2025-9, with early advice and lifecycle evidence planning
What Swissmedic Fast-Track Means for Clinical Trial Sponsors
Swissmedic swissethics Fast-Track Pilot Project accelerates eligible trial reviews and makes coordinated regulatory preparation increasingly important.
FDA Breakthrough Device Acceleration
How innovative MedTech companies can accelerate FDA approval, secure Medicare coverage, and reach patients faster—starting with Breakthrough Device Designation.
The contribution of patient associations in clinical trials
Historically, patient organizations have had the primary purpose of supporting the communities they represented. Today, this remains a crucial function, but modes have changed, as has the role that associations and patients themselves take on [...]
This article provides general information and does not constitute regulatory or legal advice. Requirements should be confirmed for the specific study, applicable regulatory framework, and markets concerned.
